Arrowhead Pharmaceuticals, Inc. (ARWR)
Automate Your Wheel Strategy on ARWR
With Tiblio's Option Bot, you can configure your own wheel strategy including ARWR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARWR
- Rev/Share 4.2906
- Book/Share 5.1377
- PB 7.8693
- Debt/Equity 0.2168
- CurrentRatio 4.8677
- ROIC -0.0916
- MktCap 4067550360.0
- FreeCF/Share -0.1267
- PFCF -230.8354
- PE -27.561
- Debt/Assets 0.0816
- DivYield 0
- ROE -0.4119
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone.
Read More
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) H.C. Wainwright 27th Annual Global Investment Conference September 9, 2025 10:30 AM EDT Company Participants Dr. Christopher Anzalone - Chairman, CEO & President James Hamilton - Chief Medical Officer and Head of R&D Conference Call Participants Patrick Trucchio - H.C.
Read More
Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Positive
Arrowhead stock is a Strong Buy due to significant pipeline progress, especially the upcoming FDA PDUFA review date of plozasiran for familial chylomicronemia syndrome. The PALISADE phase 3 trial for plozasiran showed robust efficacy in reducing triglycerides and acute pancreatitis risk, leading to an FDA PDUFA review date of November 18, 2025. Ongoing late-stage studies for severe hypertriglyceridemia (SHTG) and a lucrative Novartis partnership for ARO-SNCA further strengthen company's long-term growth prospects.
Read More
Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences
Published: August 27, 2025 by: Business Wire
Sentiment: Neutral
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: European Society of Cardiology (ESC) Congress 2025 – August 29 - September 1, 2025 Title: A Randomized, Placebo-controlled Phase 3 Study of Plozasiran in Patients With FCS: Interim Analysis of Open Label Extension of PALISADE at 1 Year Date/Time: August 30, 2025, 5:15 pm CET Type: Moderated Poster Presentation Title: Safety and E.
Read More
Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2025 Earnings Call Transcript
Published: August 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q3 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise Bruce D. Given - Corporate Participant Chief Medical Scientist - Corporate Participant Christopher R.
Read More
How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Negative
Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price due to concerns over milestone payments and clinical program continuity. Arrowhead's financial position remains strong, even with a reduced runway caused by the lack of promised milestone payments from Sarepta. In today's article, I discuss a range of potential outcomes for the collaboration between Sarepta Therapeutics and Arrowhead Pharmaceuticals and what Arrowhead can do with its pipeline and financials.
Read More
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
Published: June 23, 2025 by: Business Wire
Sentiment: Neutral
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned su.
Read More
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events: BofA Securities 2025 Health Care Conference – May 13-15, 2025 Type: Fireside Chat Presentation Date/Time: May 14, 2025, 11:20 a.m. PDT 2025 RBC Capital Markets Global Healthcare – May 20-21, 2025 Type: Fireside Chat Presentation Date/Time: May 20, 2025, 2:35 p.m. EDT Presentation webcasts may be accessed on the Events an.
Read More
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Positive
Arrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with a phase 3 trial plan in homozygous familiar hypercholesterolemia patients. We could see as many as three phase 1/2 readouts this year from programs that were recently partnered with Sarepta, and ARO-DM1 program milestones point to registrational intent.
Read More
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardio/Metabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Luca Issi - RBC Capital David Lebowitz - Citi Jasmine Fels - UBS Maury Raycroft - Jefferies Edward Tenthoff - PSC Patrick Trucchio - H.C. Wainwright Mayank Mamtani - B.
Read More
About Arrowhead Pharmaceuticals, Inc. (ARWR)
- IPO Date 1993-12-16
- Website https://arrowheadpharma.com
- Industry Biotechnology
- CEO Christopher R. Anzalone
- Employees 609